News & Events

Published On: 10/11/2021

Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021

Target RWE participated in the virtual United European Gastroenterology (UEG) Week in October 2021 to share new real-world data findings from a recent TARGET-IBD poster- Histological Inflammation Predicts Loss of Remission Among Crohn’s Patients with Endoscopic Remission: A US Cohort Analysis.

The TARGET-IBD analysis focused on assessing the associations between clinical characteristics and loss of remission (LOR) in a real-world US-based cohort of Crohn’s disease (CD) patients in endoscopic remission. The analysis found that 53.8% of patients experienced LOR during follow-up to second colonoscopy. In addition, ileal disease at index was significantly associated with future LOR compared to isolated colonic disease. Furthermore, evidence of histologic inflammation was associated with twice the odds of LOR and was a predictor of subsequent LOR.

“The findings presented at UEG Week highlight the need for future research to be more focused on determining if treatment modification or intensification is effective at preventing LOR in patients with risk factors,” said Julie M. Crawford, MD, Senior Director of Scientific and Medical Affairs.

TARGET-IBD is an active 5-year longitudinal, observational study of more than 4,600 adult and pediatric patients with IBD receiving usual care from 36 academic and community centers throughout the U.S. Real-world data is collected retrospectively for three years from the time of the patient's date of consent and patients are also followed prospectively for a minimum of five years. The robust TARGET-IBD cohort allows for the collection of effectiveness and safety data upon new drug approvals.

Learn more about Target RWE’s publications here.

About Target RWE

Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.

Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit


Kayla Slake
Marketing Manager

984.234.0268 ext 205